Alpine Immune Sciences, Inc. is focused on developing novel protein‐based immunotherapies using its proprietary Variant Ig Domain vIgD platform technology. The vIgD platform is designed to interact with multiple targets, including many present in the immune synapse. Alpine’s vIgDs are developed using a process known as directed evolution, which can potentially produce proteins capable of either enhancing or diminishing an immune response and thereby may potentially apply therapeutically to both oncology and inflammatory diseases. The company formed following a July, 2017 merger with Nivalis Therapeutics.
Know what you own, and know why you own it. - Peter Lynch According to Warren Buffett, being patient and waiting for the right opportunity is the key to successful long-term investing. Resonating with the principle is my investing story with Alpine Immune Sciences (ALPN). As you know, Mr. Buffett...
BioSci Capital Partners on Seeking Alpha | January 5, 2021
Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Director Orbimed Advisors Llc sold 600,000 shares of the firm’s stock in a transaction that occurred on Monday, December 28th. The shares were sold at an average price of $14.25, for a total transaction of $8,550,000.00. The sale was disclosed in a filing with the SEC, which is available through […]
If you're like me, you're an eternal optimist when it comes to the march of scientific progress and its ability to improve human life. The stocks that I'll discuss today are micro-cap stocks, which means that they have market capitalizations between $50 million and $300 million. Think of them as early stage public companies that don't have much consistent revenue yet.